The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer that provides better long-term stability for AAVs is a crucial step in the process of developing a clinic-bound therapeutic. Join Dr. Igor Oruetexebarria, senior scientist at Kuopio Center for Gene and Cell Therapy, as he walks through some of the current challenges in the field of gene therapy AAV development, and explains how the nanoDSF and DLS capabilities of the Prometheus Panta have improved the outcomes for his vector candidates.
Ready to tackle your challenging stability characterizations?Discover tools
See more related content
Choosing the right stability characterization tool for your biologics research is a big commitment. You’re going to be screening and optimizing lots of candidates, and you’ll need data on thermal stab
As a gene therapy scientist, you face an abundance of challenges when working to build an effective AAV therapeutic. Many steps of the development workflow have yet to be standardized and the...
When you develop an AAV therapeutic, you need to assess many key parameters, or Critical Quality Attributes (CQAs), in order to track progress and, ultimately, get your therapeutic approved. As part
With the first AAV-based gene therapies approved, and new gene editing strategies emerging, it’s important to stay on top of the latest topics in this therapeutic area. Here are 8 gene therapy...
SOUTH SAN FRANCISCO, Calif Feb 16 2022 — NanoTemper Technologies today announced the addition of Static Light Scattering (SLS) to their wildly successful Prometheus Panta, turning their instrument...
Join this webinar to learn about the physical phenomenon that drives Dynamic Light Scattering (DLS), and see a few examples of how DLS gives you deeper insights.
Learn what attributes Prometheus users considered a must-have and how we made sure to preserve them when integrating and implementing new biophysical techniques. Prometheus Panta gives you the ability